Minimally invasive treatment modalities for life-threatening haemoptysis in patients unresponsive to medical interventions and/or in patients deemed functionally inoperable are limited. We describe the implantation of endobronchial valves in a patient with recurrent haemoptysis, which presents both a novel indication for the use of these devices and a novel intervention for haemoptysis. Our patient is a 30-year-old male who developed bilateral upper lobe aspergillomata following previous pulmonary tuberculosis. The patient had a history of multiple hospitalisations for life-threating haemoptysis despite repeated bronchial artery embolisations. He was deemed to be inoperable given the bilateral nature of his disease and very poor pulmonary reserves. We proceeded to identify the segments involved with the aid of computed tomography reconstruction and implanted 3 endobronchial valves. Our patient remained haemoptysis free for 6 months and experienced no stent-related complications. Moreover, he was subsequently employed as a manual labourer and showed significant improvements in his functional capacity. Endobronchial valves may therefore represent a viable medium-term treatment option as a blockade device in patients unresponsive to medical interventions and/or in patients deemed functionally inoperable. Prospective studies are indicated to better delineate the role of endobronchial valves in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000355198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bronchoscopic lung volume reduction complicated by ipsilateral pleural effusion.
Respir Med Case Rep
December 2024
Section of Pulmonary, Critical Care and Sleep Medicine Carilion Clinic, Virginia Tech School of Medicine, USA.
Chronic obstructive lung disease is the third leading cause of death worldwide. It affects the airways and lung parenchyma leading to emphysema. Bronchoscopic lung volume reduction is another strategy that aims to reduce air trapping and hyperinflation, leading to improvement in symptoms and pulmonary function.
View Article and Find Full Text PDFOutcome and safety 90 days after combined airway valve treatment of the right upper and middle lobes in patients with severe pulmonary emphysema.
Respir Res
January 2025
Department of Pneumology and Critical Care Medicine, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany.
Background: In COPD patients with severe right-sided emphysema, complete major and incomplete minor fissure, implantation of one-way valves in both the right upper (RUL) and middle lobes (ML) is a possible approach for endoscopic lung volume reduction. The aim of this retrospective analysis was to evaluate the response to therapy and the complication rate at 90 days (90d-FU) after combined RUL-ML valve implantation.
Methods: This retrospective, monocentric study included all patients from the Thoraxklinik Heidelberg who underwent RUL-ML valve treatment between 2012 and 2023 with available follow-up data.
Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis.
Lung
January 2025
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
Article Synopsis
- The systematic review examines surgical and bronchoscopic options for lung volume reduction in patients with severe emphysema, comparing their effectiveness and associated risks.
- It includes data from 25 randomized controlled trials involving over 4,000 patients, revealing that lung volume reduction surgery (LVRS) led to significant improvements in lung function and exercise capacity but also increased mid-term mortality risks.
- The findings suggest that while endobronchial valve (EBV) and endobronchial coil (EBC) procedures showed notable benefits similar to LVRS in lung function improvements, they also carry a higher risk of pneumothorax and slightly increased mortality, highlighting the need for further long-term survival studies for bronchoscopic interventions.
Real-Life Nationwide Outcomes of Bronchoscopic Lung Volume Reduction with Endobronchial Valves in Severe Chronic Obstructive Pulmonary Disease.
Respiration
December 2024
Department of Medicine, Lillebaelt Hospital Vejle, University Hospital of Southern Denmark, Vejle, Denmark.
Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, characterized by airflow limitation and lung hyperinflation due to emphysema. Bronchoscopic lung volume reduction (BLVR) with endobronchial valves offers a minimally invasive treatment option for emphysema, aiming to reduce lung hyperinflation, thereby improving lung function and exercise tolerance.
Methods: This study evaluated the efficacy of BLVR in a real-life nationwide setting using comprehensive Danish registries.
Lung volume reduction: surgery endobronchial valves.
Breathe (Sheff)
October 2024
Program of Minimally Invasive Thoracic Surgery and New Technologies, Policlinic Hospital, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Volume reduction is a disease-modifying treatment that aims to reshape the diseased lung towards a more normal total lung capacity by removing severely damaged and overinflated lung parenchyma. It is an effective therapeutic strategy in well-selected patients, resulting in improvements in exercise tolerance, lung function, quality of life and survival. The most widespread strategies for volume reduction are either video-assisted thoracoscopic surgery or bronchoscopic lung volume reduction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!